Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories
-
Allakos Inc. (ALLK) PT Lowered to $10 at Cantor Fitzgerald, But BUY Rating Maintained, "Still Believe that the Market Opportunity for lirentelimab is Underappreciated"
-
Cantor Fitzgerald Reiterates Overweight Rating, $7 Price Target on VolitionRX (VNRX), Has a "More Favorable View of the Company"
-
Cantor Fitzgerald Reiterates Overweight Rating, $19 Price Target on Exagen (XGN) on Alivio Health Agreement
-
Form SC 13D/A Satellogic Inc. Filed by: CANTOR FITZGERALD, L. P.
-
Form 424B3 Cantor Fitzgerald Income
-
Appreciate to Go Public Via Merger with PropTech Investment Corporation II (PTICU)
-
Cantor Fitzgerald Reiterates Neutral Rating on TherapeuticsMD (TXMD)
-
UPDATE: Aytu Biosciences (AYTU) PT Lowered to $5 at Cantor Fitzgerald, "Overweight" Rating Reiterated, Analyst Expects "Upwards Earnings Revisions Should Drive Shares Higher"
-
Spero Therapeutics (SPRO) PT Slashed to $5 at Cantor Fitzgerald, Analyst Maintains "Overweight" Rating
-
Form 13F-NT CANTOR FITZGERALD & CO. For: Mar 31
-
Form 13F-HR CANTOR FITZGERALD, L. For: Mar 31
-
Form 13F-NT CANTOR FITZGERALD SECURI For: Mar 31
-
Form 13F-NT Cantor Fitzgerald Europe For: Mar 31
-
Form 10-Q Cantor Fitzgerald Income For: Mar 31
-
Form SC 13G Cartesian Growth Corp Filed by: CANTOR FITZGERALD SECURITIES
-
Cantor Fitzgerald Reiterates Overweight Rating. $15 Price Target on ContraFect (CFRX), "Expect Upwards Earnings Revision to Move Share Higher"
-
UPDATE: Benchmark Downgrades Shift Technologies Inc. (SFT) to Hold
-
Lionheart Acquisition Corporation II (LCAPU) Enters Non-Binding Term Sheets for Forward Purchase Agreement and Committed Equity Facility with Cantor Fitzgerald
-
Cantor Fitzgerald Assumes Poseida Therapeutics, Inc (PSTX) at Overweight
-
Cantor Fitzgerald Assumes Harpoon Therapeutics (HARP) at Overweight
-
CF Acquisition Corp. VI (CFVI) and Rumble File Amended Registration Statement for Proposed Merger
-
Cantor Fitzgerald Reiterates VYNE Therapeutics (VYNE) at Overweight with $10 Price Target, Expects "Upwards Earnings Estimate Revisions and Multiple Expansion"
-
Cantor Fitzgerald Reiterates Overweight Rating on Fortress Biotech (FBIO) on Q1 Report, "Risk-Diversification Remains Attractive "
-
Cantor Fitzgerald Reiterates Overweight Rating on Checkpoint Therapeutics (CKPT) on Q1 Report
-
Cantor Fitzgerald Reiterates Overweight Rating, $5 on PAVmed (PAVM), "Encourage Investors to Acquire PAVM Shares at Attractive Valuation"
-
Cantor Fitzgerald Reiterates Overweight Rating, $18 Price Target on Aravive (ARAV), "Peak Sales Potential of AVB-500 Remains Underappreciated"
-
Cantor Fitzgerald Reiterates Overweight Rating. $5 Price Target on Cidara Therapeutics (CDTX), "We Believe Street Under-appreciated Sales Potential of CDTX's Two Pipeline Assets"
-
Cantor Fitzgerald Maintains ProQR Therapeutics N.V. (PRQR) at Overweight with $3.50 Price Target
-
Form 13F-HR/A CANTOR FITZGERALD INVEST For: Mar 31
-
Curaleaf (CURLF) PT Lowered to $14.60 at Cantor Fitzgerald
-
'Welcome Relief': 3 Analysts Discuss Pfizer's $11.6 Billion Deal to Acquire Biohaven (BHVN)
-
Biotech Acquisition (BIOT) and Blade Therapeutics Announce Effectiveness of Registration Statement, Signs $75M Committed Equity Financing
-
RedHill Biopharma (RDHL) Announces 10.57M ADS Direct Offering at $1.42/ADS
-
Form 40-17G CANTOR FITZGERALD SUSTAI
-
Cartesian Growth Corporation II (RENEU) Prices 20M Unit IPO at $10/unit
-
Form 8-K Cantor Fitzgerald Income For: May 02
-
Form 4 Cantor Fitzgerald Income For: May 02 Filed by: LUTNICK HOWARD W
-
Cantor Fitzgerald Reiterates Overweight Rating on SeaSpine Holdings (SPNE) Following Q1 Report, Sees "Likely Share Price Appreciation"
-
Form 424B3 Cantor Fitzgerald Income
-
Pfizer (PFE) Sales Beat Estimates on Robust Covid Vaccine Sales; Analyst Weigh In on Results
-
Cantor Fitzgerald Reiterates Overweight Rating, $85 Price Target on Cutera (CUTR)
-
Form 10-K/A Cantor Fitzgerald Income For: Dec 31
-
UPDATE: Cantor Fitzgerald Downgrades Emergent BioSolutions (EBS) to Neutral
-
Sono Group (SEV) Prices 10M Share Follow-on Offering at $4/sh
-
UPDATE: Cantor Fitzgerald Starts Roivant Sciences (ROIV) at Overweight
-
Cantor Fitzgerald Reiterates Overweight Rating, $21 Price Target on SeaSpine Holdings (SPNE)
-
Cantor Fitzgerald Reiterates Overweight Rating, $12 Price Target on Lucid Diagnostics Inc (LUCD) on BeiGene's RATIONALE 306 Trial Data, "Encourage Investors to Acquire LUCD Shares at an Attractive Ent
-
Veru (VERU) and Opiant (OPNT) Top Cantor Fitzgerald's List of Largest Short Interest Increases
-
Sono Group (SEV) Announces 10M Share Follow-on Offering
-
Form SC 13G Arbor Rapha Capital Bioh Filed by: CANTOR FITZGERALD SECURITIES